- Report
- April 2025
- 93 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 324 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 244 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 193 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 184 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 246 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 197 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 179 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 194 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 553 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 170 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 480 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 392 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 273 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 194 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 466 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 565 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 283 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 74 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 150 Pages
Global
From €4414EUR$4,850USD£3,749GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more